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Abstract
Background: Heart failure with preserved ejection fraction (HFpEF) is less well understood than heart 
failure with reduced ejection fraction (HFrEF), with greater diagnostic difficulty and management 
uncertainty.
Aim: The primary aim is to develop an optimised programme that is informed by the needs and 
experiences of people with HFpEF and healthcare providers. This article presents the rationale and 
protocol for the Optimising Management of Patients with Heart Failure with Preserved Ejection 
Fraction in Primary Care (OPTIMISE- HFpEF) research programme.
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Design & setting: This is a multi- method programme of research conducted in the UK.
Method: OPTIMISE- HFpEF is a multi- site programme of research with three distinct work packages 
(WPs). WP1 is a systematic review of heart failure disease management programmes (HF- DMPs) tested 
in patients with HFpEF. WP2 has three components (a, b, c) that enable the characteristics, needs, 
and experiences of people with HFpEF, their carers, and healthcare providers to be understood. 
Qualitative enquiry (WP2a) with patients and providers will be conducted in three UK sites exploring 
patient and provider perspectives, with an additional qualitative component (WP2c) in one site to 
focus on transitions in care and carer perspectives. A longitudinal cohort study (WP2b), recruiting from 
four UK sites, will allow patients to be characterised and their illness trajectory observed across 1 year 
of follow- up. Finally, WP3 will synthesise the findings and conduct work to gain consensus on how best 
to identify and manage this patient group.
Results: Results from the four work packages will be synthesised to produce a summary of key learning 
points and possible solutions (optimised programme) which will be presented to a broad spectrum of 
stakeholders to gain consensus on a way forward.
Conclusion: HFpEF is often described as the greatest unmet need in cardiology. The OPTIMISE- 
HFpEF programme aims to address this need in primary care, which is arguably the most appropriate 
setting for managing HFpEF.
How this fits in
HFpEF is poorly recognised and managed in the community. As HFpEF is set to become the dominant 
form of heart failure (HF), it is vital that effective primary care- based programmes of identification and 
management are developed. The OPTIMISE- HFpEF programme of research aims to fill this void.
Introduction
HFpEF is less well understood than HFrEF and is associated with greater diagnostic difficulty and 
management uncertainty.1 Half of all HF cases may be attributable to HFpEF, and prevalence is rising 
at a rate of 1% annually.1–3 Although mortality for all- cause HF in the UK has modestly improved, no 
treatment has yet been shown to improve mortality and morbidity in HFpEF.4,5 Lack of evidence for 
pathophysiological mechanisms underpinning the disease, effective pharmacotherapies, and disease 
management programmes specifically targeting HFpEF hamper progress. It is perhaps unsurprising 
then that clinicians may, to coin Oktay and Shah, 'approach HFpEF with diagnostic and therapeutic 
nihilism'.6
This article presents the rationale and protocol for the OPTIMISE- HFpEF research programme 
(https://www. optimisehfpef. phpc. cam. ac. uk/), in line with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement.7 This project aims to explore the views 
of people with HFpEF and the multiple stakeholders involved in HFpEF care; phenotype a UK cohort; 
and undertake consensus methods to develop an optimised programme that would provide guidance 
to clinicians in diagnosing and managing HFpEF.
Background and rationale
The emergence of HFpEF as a clinical syndrome has been, and continues to be, controversial.4 
There are uncertainties along the entire spectrum from mechanisms and diagnosis to treatment 
and management. Understanding of underlying pathophysiological processes continues to develop 
through research, and varying models have been proposed to explain the abnormal cardiac structure 
and function observed.2,4,8 The current preferred paradigm is that microvascular endothelial 
inflammation, driven by coexisting conditions, leads to myocardial inflammation and fibrosis that in 
turn results in increased oxidative stress and alterations in cardiomyocyte signalling.2,8 Diagnostically, 
while definitions and criteria have been tightened, universal consensus and a definitive algorithm are 
lacking.9–11 In treatment terms, evidence- based pharmacological therapies and device options are 
limited and developments lag behind those observed in HFrEF.4 Disease management programmes 
consistently demonstrating reduced mortality and re- hospitalisation rates in HF do not frequently 
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include or explicitly analyse data on HFpEF;12,13 therefore, benefits observed cannot confidently be 
extrapolated. Lastly, a persistent gap between best and current practice exists, which is compounded 
by a lack of integrated care.14–16
The outcome of these challenges in HFpEF is high rates of hospitalisation, mortality, poor 
functioning, and low quality of life.3,17 Some authorities have already called for dedicated HFpEF 
clinical programmes, and lessons will be garnered from pioneering initiatives.18 However, while they 
acknowledge the necessity of the primary care provider, there is a lack of specificity and focus on the 
role of general practice.
General practice has a key role in all parts of the HF patient pathway, from initiating diagnosis to 
long- term management;19,20 a pathway enshrined in national guidelines.21,22 However, even national 
guidelines pay sparse attention to HFpEF, dedicating the majority of the content to HFrEF (see 
Appendix A in supplementary materials for an overview of current recommendations). They do not 
address or troubleshoot many of the key issues debated in HFpEF research; for example, the lack of 
specificity of echocardiogram to accurately capture diastolic left ventricle dysfunction,23–25 the frequent 
absence of echocardiographic evidence of structural heart disease in invasively confirmed HFpEF,26 
and the poor sensitivity of natriuretic peptides in HFpEF.27,28 All the latter are key components of 
HFpEF diagnostic algorithms in the UK. Moreover, they lack the necessary focus on exercise, which 
has pleiotropic effects on systemic endothelial function and therefore improves symptoms and quality 
of life.29
Others have already argued an effective pathway to achieve cohesive primary and/or specialist 
co- management remains elusive and the current structure of care is suboptimal.30 In HFpEF, the need 
to establish this is ever more pressing given the increasing prevalence, the burden of multimorbidity, 
and the complex interplay of medical, psychological, behavioural, and social factors for this group.31 
Optimally managing a vulnerable and complex population of older adults, in a pragmatic and patient- 
centred way, is arguably better addressed by generalists familiar with patient preferences and priorities 
and the application of comprehensive and multidimensional assessment.32
Why this research is needed
HFpEF is poorly recognised and managed in the community. As HFpEF is set to become the dominant 
form of HF, it is vital that effective primary care- based programmes of identification and management 
are developed. The OPTIMISE- HFpEF programme of research aims to fill this void by: (1) finding 
out what patients and providers want; (2) understanding what people with HFpEF are like in the UK, 
through detailed phenotypic characterisation of a large cohort; and (3) exploring common problematic 
areas like transitions of care (any move from one care setting to the next, most often hospital to 
home), hospitalisations, and the support of carers (see Table 1). Results generated will be synthesised, 
and both face- to- face and online consensus methods employed to develop and refine an optimised 
programme of management.
Aim
The primary aim is to investigate HFpEF with the view to developing an optimised programme that is 
informed by the needs and experiences of people with HFpEF and healthcare providers. A secondary 




An optimised programme would constitute a complex intervention; therefore, the multi- stage cyclical 
process consisting of four key elements outlined by the Medical Research Council (MRC) has been 
adopted.33 The resulting mixed- methods approach consisting of five WPs is cognisant of these key 
elements (see Table 1 and Figure 1) and has been designed to maximise opportunities for theorising, 
iterative development, and pragmatic modelling of contextual, organisational, and logistical factors. 
Each of the WPs also has ‘legacy elements’; therefore, the emerging programme of care can be 
tested and critiqued by ‘end users’, either qualitatively via networks and cohorts of patients, carers, 
and providers (WP2a and WP2c), or quantitatively in an established cohort of HFpEF patients (WP2b).
Forsyth F et al. BJGP Open 2019; DOI: 10.3399/bjgpopen19X101675
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Table 1 Work package details
MRC complex intervention stage 
mapping
WP1 Description Systematic review of disease management programmes tested in HFpEF 
populations (see Prospero: CRD42017067980).
Identifying the evidence base.
Location Cambridge, UK
Recruitment N/A
Data collection Commenced October 2017 – completed September 2019
WP2a Description Qualitative interview study to determine patient and health professionals’ 
preferences, perspectives on burden of illness and treatment, care 
requirements, and organisation of services and/or support in HFpEF.
Identifying and/or developing 
theory.
Modelling process and outcomes.
Location Collaborative, multi- site study involving Cambridge, Keele, and Manchester 
(UK). Sites are utilising the NIHR Primary Care Research Network to identify 
general practices in their region through which recruitment of patients and 
primary care clinicians will be managed. Secondary and primary care- based HFS 
services will be approached to augment recruitment. Other healthcare providers 
and commissioners will be identified via local networks.
Recruitment Commenced October 2017 – planned end March 2020
Data collection Data collection involves face- to- face or telephone interview with patients ±their 
carers and healthcare professionals managing or structuring care for patients 
with HFpEF, including but not limited to HFS nurses, cardiologists, GPs, practice 
nurses, healthcare commissioners, and rehabilitation specialists.
WP2b Description Prospective longitudinal observational cohort study that will identify probable 
HFpEF patients, confirm HFpEF status, characterise the cohort at baseline, and 
prospectively follow- up confirmed HFpEF cases for 1 year.
Modelling process and outcomes.
Estimate recruitment and retention.
Determine sample size
Preliminary testing of procedures.
Location Collaborative, multi- site study involving the Universities of Cambridge and 
Oxford, and Cardiology/Care of the Elderly services at North West Anglia and 
Guy’s and St. Thomas’ NHS Foundation Trust. Cambridge and Oxford will utilise 
the NIHR Primary Care Research Network to identify general practices in their 
region through which recruitment of patients will be managed.
Recruitment Commenced July 2018 – planned end July 2020.
Data collection Data collection involves a baseline visit where a diagnostic echocardiogram 
will be performed (previously performed diagnostic echocardiograms will be 
used at secondary care sites) to confirm the presence or absence of HFpEF. 
Additional assessments at baseline are described in Table 2.
WP2c Description Qualitative interview sub- study employing a framework analysis approach to 
explore hospitalisation in HFpEF patients, transitions of care, and their carers’ 
perspectives.
Identifying and/or developing 
theory.
Modelling process and outcomes.
Location Sub- study within the Cambridge longitudinal cohort sample.
Recruitment Commenced December 2018 – planned end July 2020.
Data collection Data collection involves face- to- face interviews with patients and their carers. 
Basic demographic information and interview notes and/or reflections will also 
be collected.
WP3 Description Summary statement and questions presented to stakeholders to gauge 
consensus, explore disparity, identify sticking points, and elicit programme 
refinements.
Identifying and/or developing 
theory.
Modelling process and outcomes.
Preliminary testing of procedures.
Understanding change process.Location UK- wide, diverse sample of non- collocated 'experts' with various levels and 
domains of expertise (including but not limited to: patients, primary care 
physicians, cardiologists, echocardiography specialists, HFS, and heart failure 
charities).
Recruitment Commenced April 2019 – planned end December 2020.
Data collection Using a structured online system, the experts will be asked to discuss the 
summary statement. Comments are aggregated, then quantitatively and 
qualitatively analysed using statistical modelling techniques to enable decision- 
making based on the input from the expert panellists.
PROSPERO is the international prospective register of systematic reviews, accessible at https://www.crd.york.ac.uk/prospero/
HFpEF = heart failure with preserved ejection fraction. HFS = heart failure specialist. MRC = Medical Research Council. N/A = not applicable. NIHR = National 
Institute for Health Research. WP = work package.
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Setting
Multiple sites were involved to enhance the diversity of the sample in each cohort (see Table 1).
Participants
Participants in WP2a and WP2b must meet the following inclusion criteria: adult patients with 
diagnosed or suspected HFpEF, and the ability to communicate in English. Diagnosed or suspected 
HFpEF was defined as anyone diagnosed with non- valvular HF that (i) were not diagnosed with left 
ventricular systolic dysfunction or have a documented ejection fraction (EF) <50%; or (ii) have a 
reported ‘normal’ or preserved EF (that is, >50%); or (iii) have an echocardiogram reporting structural 
heart disease or diastolic dysfunction without moderate to severe systolic dysfunction. Although 
the European Society of Cardiology guideline is used to diagnose HFpEF9 in WP2b, this pragmatic 
definition was employed given the literature detailing the challenges of identifying patients with HF 
from primary care records.34–36
The following exclusion criteria were applied to WP2a and WP2b: any severe neurocognitive 
condition that would confound outcome assessment; New York Heart Association class IV classification; 
or other life- threatening condition. Heart failure exacerbations resulting in hospitalisation in the 6 
weeks before screening were included in WP2b owing to the nature of the physical assessments. 
Participants in WP2c will include patients from WP2b who have a confirmed diagnosis of HFpEF 
and have experienced hospitalisation for HF or a comorbid condition. Adult carers will be invited via 
patient participants. No specific inclusion or exclusion criteria will be applied to WP3, with the aim of 
recruiting a heterogeneous panel representative of a range of views.
Patients with HFpEF in WP2a and WP2b will be identified with the support of the National Institute 
for Health Research Clinical Research Networks (NIHR CRN). In brief, the NIHR CRN offers a range 
of support to help researchers plan, set up, and deliver research. In this case, assistance was sought 
to gain access to general practices that were provided with an electronic medical record screening 
Figure 1 OPTIMISE- HFpEF programme of research
HFpEF = heart failure with preserved ejection fraction. WP = work package.
Forsyth F et al. BJGP Open 2019; DOI: 10.3399/bjgpopen19X101675
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algorithm to enable identification of potential participants. A GP within the practice screened against 
the inclusion and exclusion criteria before inviting eligible patients. Patients interested in taking 
part were asked to return an expression of interest form to the research team. The research team 
contacted those interested to discuss the study in detail (including any risks and/or benefits, and right 
to withdraw) before written informed consent was sought (see Figure 2). Purposive sampling will 
be used in WP2c to target patients with confirmed HFpEF that have experienced a hospitalisation; 
snowball sampling will be used to recruit their carers. The WP3 sample will be recruited via current 
WPs and local networks.
A patient advisory group is active within the study, and continues to provide input.
Variables and data sources
WP1 was a systematic review of controlled studies of HF- DMPs that included patients with HFpEF. 
Four bibliographic databases were searched, yielding 6089 titles that were screened against an 
agreed protocol (see PROSPERO https://www. crd. york. ac. uk/ prospero/). Eighteen studies met the 
inclusion criteria, representing 1866 patients with HFpEF. All studies were assessed against a ‘disease 
management programme taxonomy’ and scored for complexity, intensity, and bias. The review 
Figure 2 Flow of participants
HFpEF = heart failure with preserved ejection fraction. WP = work package.
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concluded HF- DMPs may improve mortality, hospitalisation rates, self- care, and quality of life in 
patients with HFpEF; however, further research specifically tailored to HFpEF is required.
In WP2a and WP2c, sociodemographic data, interview notes and/or reflections, and interview 
recordings will form the main data sources. In WP2c, the caring relationship and arrangement will be 
documented and the Carer Support Needs Assessment Tool (CSNAT) completed.37 Hospitalisations 
will be validated via Hospital Episode Statistics (details of all admissions, accident and emergency 
attendances, and outpatient appointments at NHS hospitals in England).
WP2b will collect sociodemographic, behavioural, clinical, and quality- of- life data at baseline, 6, 
and 12 months (Table 2). The aim is to phenotype and follow a UK cohort over a 1- year period. As 
such, there is no primary outcome or comparison; analysis will be descriptive and exploratory. To date, 
much of the insight into the clinical characteristics of HFpEF comes from randomised controlled trials 
of drug therapies. Such studies have stringent inclusion criteria that exclude the very old and those 
with significant multimorbidity or functional impairments — arguably the ‘typical’ patient with HFpEF.20 
Refined characterisation of a representative, real- world cohort will help with effective targeting of the 
components in the final programme of care.
The results of findings from all the WPs will be integrated to produce a position article that will 
form the basis of the questions presented in the modified Delphi online elicitation approach. This 
methodology produces ratings and rankings of statements as well as qualitative online discussion data 
from expert panel members.
Bias and fidelity
All study procedures will be conducted in accordance with the respective protocols (see https://www. 
optimisehfpef. phpc. cam. ac. uk/) and in line with the principles outlined in the International Conference 
on Harmonisation Good Clinical Practice guideline.38 WP2a and WP2c will use a semi- structured 
interview template that will guide the interview process while also allowing flexibility for exploration 
of specific issues. WP2b has a comprehensive Manual of Operations and Procedures to standardise 
practice in relation to outcome measure collection.
Study size
WP2a will recruit up to 100 patients and healthcare professionals. WP2c will recruit 40 previously 
hospitalised patients with HFpEF and their carers. The sample size for the qualitative components is 
an approximation of the number of subjects required based on previous research; the adequacy will 
be evaluated during the research process.39
The planned sample size in WP2b is 270 patients. This estimate is based on exemplar calculations 
to ensure confidence in the estimates of characteristics and changes in measures over 1 year, but is 
also cognisant of practical logistical considerations and rapidly changing diagnostic criteria in HFpEF. 
Previous research has demonstrated difficulty in confirming HFpEF from primary care records owing 
to the absence of diagnostic information.30 Based on this, it is estimated up to around 25% of referred 
patients will not have HFpEF after cardiologist review of baseline data. The final sample size was not 
adjusted for attrition.
Statistical and qualitative analysis methods
The main data source in WP2a and WP2c will be qualitative semi- structured interview recordings 
and verbatim transcripts. These will be analysed using the framework method40 to gain insight into 
the perspectives of patients receiving HFpEF care and their carers, and of primary and secondary 
healthcare providers planning and delivering that care across three regions in England. The 
framework method employs a structured approach and the main output — a matrix of charted cases, 
codes, and summarised data excerpts — enables researchers to ‘systematically reduce’ the data 
to aid interpretation.40,41 Data will be organised in NVivo (version 12) and Microsoft Excel (version 
14.0.7237.5000) software. A thematic framework (coding scheme) will be developed, before indexing, 
charting, describing, and interpreting the data.40,41 The analysis will be both inductive (data- driven) 
and deductive (theory- driven), with burden of treatment and minimally disruptive medicine models 
employed as sensitising frameworks.42,43 WP2c will follow a similar analysis pathway; deductive analysis 
will be driven by burden of treatment theory (hospitalised patients) and the CSNAT (carers).
Forsyth F et al. BJGP Open 2019; DOI: 10.3399/bjgpopen19X101675
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Table 2 WP2b clinical and behavioural variables
Parameter Measure Description
Physical characteristics Anthrop Height in centimetres, weight in kilograms, BMI kg/m2
Vitals Blood pressure (mmHg)
Respiratory rate (breaths per minute)
Pulse rate (beats per minute)
Past medical history N/A Past and current medical problems and medications will be extracted from primary and secondary care 
records
Clinical events HES Hospital Episode Statistics (date, length of time and index reason for hospitalisations, accident and 
emergency attendances, and outpatient appointments)
Heart function ECG 12- lead ECG
Echo Detailed echocardiogram with high- quality diastolic and right ventricle functional assessment
Arterial stiffnessa PWV A validated reproducible technique to investigate the clinical relevance of vascular and arterial 
stiffness36
Peripheral oedema N/A Clinical assessment of oedema including level (extent) and presence or absence of pitting
Breathlessness and fatigue mBORG Valid, reliable measure of the intensity of the sensation of breathlessness and fatigue37
Frailty CFS A validated measure of frailty based on clinical judgment38
SHARE- FI A validated automated instrument that generates a pre- calculated, population- representative, and sex- 
specific frailty class39
eFI eFI uses routine medical record data to identify older people with mild, moderate, and severe frailty 
and will be abstracted from primary care records40
Comorbidity CCI Widely used validated measure of 1- year mortality risk and burden of disease41
Cognition MoCA The MoCA is a brief cognitive screening tool with high sensitivity and specificity for detecting mild 
cognitive impairment42
Physical functioning and 
activity
6MWT A standardised submaximal test of aerobic capacity, validated in multiple populations and conditions43
GS Gait speed measured over 10 metres, a valid objective measure of functional mobility44
Acceler Objective measure of activity obtained via Axivity AX3 wrist- worn triaxial accelerometer programmed to 
start at 19:00 hours on the day of the baseline visit (to prevent capturing of protocol forced activity) and 
capture triaxial acceleration data over a 7- day period at 100 Hz with a dynamic range of +–8 g45
Laboratory testing Biochem Serum sodium, potassium, creatinine, urea, estimated GFR, random plasma glucose
Haem White and red blood cell count, haemoglobin, haematocrit, mean cell volume, mean cell haemoglobin, 
red cell distribution width, platelet count, mean platelet volume, neutrophil, lymphocyte, monocyte, 
eosinophil, basophil count
Biomarkers HbA1c An indicator of the average blood glucose concentrations over the preceding ~2  months.
NP Natriuretic peptides (NT- proBNP), a diagnostic marker in patients with heart failure
Dietary intakea Interview One 24- hour dietary recalled will be collected to ascertain over or undernutrition in HFpEF patients
Anxiety and depression HADS HADS is a widely used questionnaire that screens for the separate dimensions of anxiety and 
depression and has been validated in multiple populations32
HF QoL KCCQ KCCQ is a valid, reliable and responsive health status measure for patients with chronic heart failure that 
has been shown to have clinically meaningful changes33
HF self- care EHFScBQ A valid, reliable and practical scale to measure the self- reported self- care behaviour of heart failure 
patients.34
HF symptoms SSQ- HF Valid and reliable score to assess physical symptoms in patients with heart failure.35
Health- related QoL EQ- 5D The EQ- 5D is a widely used five- domain patient- based generic questionnaire for self- perceived health 
assessment. It describes health- related quality of life and has been extensively validated.
6MWT = 6- minute walk test. Acceler = accelerometry. Anthrop = anthropometry. Biochem = biochemistry. BMI = body mass index. CCI = Charlson comorbidity index. 
CFS = clinical frailty scale. ECG = electrocardiogram. Echo = echocardiogram. eFI = electronic frailty index. eGFR = estimated glomular filtration rate. EHFScBQ 
= European heart failure self- care behaviours questionnaire. EQ- 5D = the EuroQol 5D questionnaire. GS = gait speed. HADS = hospital anxiety and depression 
score. Haem = haematology. HbA1c = glycated haemoglobin A1c. HES = hospital episode statistics. KCCQ = Kansas City cardiomyopathy questionnaire. mBORG = 
modified BORG. MoCA = Montreal cognitive assessment. N/A = not applicable. NP = natriuretic peptides. PWV = pulse wave velocity. QoL = quality of life. SHARE- 
FI = SHARE frailty instrument. SSQ- HF = symptom status questionnaire — heart failure.
aIndicates single site sub- study.
 
 9 of 12
Research
Forsyth F et al. BJGP Open 2019; DOI: 10.3399/bjgpopen19X101675
Where possible, descriptive statistics (frequencies and proportions, mean and standard deviation, 
or median and interquartile range, as appropriate) will be presented for all WPs. In WP2b, pre- 
specified baseline comparisons will determine differences by sex, body mass, and presence of frailty. 
In addition to robust clinical information, the cohort will be described according to patient- reported 
measures on symptoms, self- management, HF specific quality of life, and physical activity. Reported 
physical activity will be validated against information from activity monitors regarding both level of 
activity and time spent sedentary. A similar analysis will be conducted with data from the 6- and 
12- month follow- up to determine changes in variables from baseline. Data on outcomes (all- cause and 
cardiovascular hospitalisations and mortality, length of stay in hospital, readmissions, and timeframes 
of readmissions) will be collected over the 12- month period.
Analysis in WP3 will be managed via an online platform, which enables quantitative, categorical, 
and text data analysis from all rounds of the elicitation and is conducted in four stages: preliminary 
data analysis, analysis of agreement, data modelling, and analysis of changes in responses.44,45
Dissemination
Dissemination of the study findings will include at least one peer- reviewed article from each WP, and 
presentations at appropriate primary care and specialist conferences.
Discussion
Summary
This multi- method programme aims to explore the views of the multiple parties involved in HFpEF 
care; to characterise a UK cohort of HFpEF patients; and to explore hospitalisation, transitions of care, 
and carer burden with a view to informing the development of an optimised programme of care. The 
optimised programme would be developed using consensus methods via an online platform that 
would refine programme components and preliminarily assess feasibility. The final programme would 
then undergo further testing in a cohort of patients with confirmed HFpEF.
Strengths and limitations
The strengths of this programme are the patient, carer, and health professional focus and the particular 
emphasis on pragmatic, primary care- based solutions. Heart failure is usually identified and managed 
long term in the primary care setting, however there is an absence of much needed guidance and 
support available for GPs. The main limitation of this project relates to testing the findings of the 
consensus work (WP3); this would be subject to future funding.
Comparison with existing literature
There is a growing body of research in HFpEF owing to its status as the 'greatest unmet need in 
cardiology’.29 However, much of this research is in the highly specialist or tertiary setting, and there is 
a dearth of literature on the role of generalists in HFpEF identification, diagnosis, and management. 
Smeets and colleagues have proposed a multi- component optimisation intervention in the primary care 
setting (OSCAR- HF pilot study); this, however is in HF generally as opposed to HFpEF specifically.46
Implications for research and practice
HFpEF is an underrecognised condition that poses many challenges for clinicians. This programme 
seeks to understand these problems from the perspective of patients, their carers, and the healthcare 
professionals who look after them, with a view to establishing an optimised programme of management 
that is cognisant of these issues.
Funding
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Ethical approval
Ethical approval has been granted for all research undertaken within each WP: 17- NE-0199 (WP2a), 
17- LO-2136 (WP2b), 18- NW-0823 (WP2c). Clinical assessments and tests undertaken in WP2b will 
be conducted in clinical settings with qualified staff and appropriate safeguards.
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ClinicalTrials. gov (reference number: NCT03617848).
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